How often are nonenhancing supratentorial gliomas malignant? A population study
Abstract
The presence of contrast enhancement in a brain tumor is often regarded as a sign of malignancy. The authors identified 314 patients with malignant and low-grade supratentorial glial neoplasms in an unselected population, 58 of which lacked contrast enhancement on preoperative neuroimaging. Nonenhancing gliomas were malignant in approximately one third of cases, especially in older patients. Histologic confirmation of the diagnosis is therefore important in all patients suspected of harboring a primary glial neoplasm.
Get full access to this article
View all available purchase options and get full access to this article.
References
1.
Chamberlain MC, Murovic JA, Levin VA. Absence of contrast enhancement on CT brain scans of patients with supratentorial malignant gliomas. Neurology . 1988; 38: 1371–1374.
2.
Kondziolka D, Lunsford LD, Martinez AJ. Unreliability of contemporary neurodiagnostic imaging in evaluating suspected adult supratentorial (low-grade) astrocytoma. J Neurosurg . 1993; 79: 533–536.
3.
Perez-Cruet MJ, Adelman L, Anderson M, Roth PA, Ritter AM, Saris SC. CT-guided stereotactic biopsy of nonenhancing brain lesions. Stereotact Funct Neurosurg . 1993; 61: 105–117.
4.
Mihara F, Numaguchi Y, Rothman M, Kristt D, Fiandaca M, Swallow L. Non-enhancing supratentorial malignant astrocytomas: MR features and possible mechanisms. Radiat Med . 1995; 13: 11–17.
5.
Perry JR, Tien RD, McLendon RE, Rasheed K, Brown MT. Argument for stereotactic biopsy of suspected low-grade glioma: results from 53 nonenhancing lesions. Neurology . 1996; 46: A158.Abstract.
6.
Barker FG II, Chang SM, Huhn SL, et al. Age and the risk of anaplasia in magnetic resonance-nonenhancing supratentorial cerebral tumors. Cancer . 1997; 80: 936–941.
7.
Ginsberg LE, Fuller GN, Hashmi M, Leeds NE, Schomer DF. The significance of lack of MR contrast enhancement of supratentorial brain tumors in adults: histopathological evaluation of a series. Surg Neurol . 1998; 49: 436–440.
8.
Lee Y-Y, Van Tassel P. Intracranial oligodendrogliomas: imaging findings in 35 untreated cases. Am J Neuroradiol . 1989; 10: 119–127.
9.
Knopp EA, Chas S, Johnson G, et al. Glial neoplasms: dynamic contrast-enhanced T2*-weighted MR imaging. Radiology . 1999; 211: 791–798.
10.
Marks JE, Gado M. Serial computed tomography of primary brain tumors following surgery, irradiation, and chemotherapy. Radiology . 1977; 125: 119–125.
Information & Authors
Information
Published In
Copyright
© 2002.
Publication History
Received: January 18, 2002
Accepted: June 5, 2002
Published online: September 24, 2002
Published in issue: September 24, 2002
Authors
Metrics & Citations
Metrics
Citation information is sourced from Crossref Cited-by service.
Citations
Download Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.
Cited By
- multiPI-TransBTS: A multi-path learning framework for brain tumor image segmentation based on multi-physical information, Computers in Biology and Medicine, 191, (110148), (2025).https://doi.org/10.1016/j.compbiomed.2025.110148
- Diagnostic performance of multiparametric nonenhanced magnetic resonance imaging (MRI) in grading glioma and correlating IDH mutation status, Clinical Radiology, 82, (106791), (2025).https://doi.org/10.1016/j.crad.2024.106791
- 3D MRI Brain Tumor Diagnosis with Topological Descriptors, Brainlesion: Glioma, Multiple Sclerosis, Stroke and Traumatic Brain Injuries, (81-94), (2024).https://doi.org/10.1007/978-3-031-76160-7_8
- Decoding Glioblastoma Heterogeneity: Neuroimaging Meets Machine Learning, Neurosurgery, (2024).https://doi.org/10.1227/neu.0000000000003260
- Beyond conventional imaging: Advancements in MRI for glioma malignancy prediction and molecular profiling, Magnetic Resonance Imaging, 112, (63-81), (2024).https://doi.org/10.1016/j.mri.2024.06.004
- Prediction of TERT mutation status in gliomas using conventional MRI radiogenomic features, Frontiers in Neurology, 15, (2024).https://doi.org/10.3389/fneur.2024.1439598
- The Current Diagnostic Performance of MRI-Based Radiomics for Glioma Grading: A Meta-Analysis, Journal of Integrative Neuroscience, 23, 5, (2024).https://doi.org/10.31083/j.jin2305100
- The Utility of Spectroscopic MRI in Stereotactic Biopsy and Radiotherapy Guidance in Newly Diagnosed Glioblastoma, Tomography, 10, 3, (428-443), (2024).https://doi.org/10.3390/tomography10030033
- Fully automated MR-based virtual biopsy of primary CNS lymphomas, Neuro-Oncology Advances, 6, 1, (2024).https://doi.org/10.1093/noajnl/vdae022
- Multiparametric MRI and T2/FLAIR mismatch complements the World Health Organization 2021 classification for the diagnosis of IDH-mutant 1p/19q non-co-deleted/ATRX-mutant astrocytoma, Clinical Radiology, 79, 3, (197-204), (2024).https://doi.org/10.1016/j.crad.2023.11.016
- See more
Loading...
View Options
Login options
Check if you have access through your login credentials or your institution to get full access on this article.
Personal login Institutional LoginPurchase Options
The neurology.org payment platform is currently offline. Our technical team is working as quickly as possible to restore service.
If you need immediate support or to place an order, please call or email customer service:
- 1-800-638-3030 for U.S. customers - 8:30 - 7 pm ET (M-F)
- 1-301-223-2300 for customers outside the U.S. - 8:30 - 7 pm ET (M-F)
- [email protected]
We appreciate your patience during this time and apologize for any inconvenience.
This article states that, "We found that 9% of nonenhancing gliomas were malignant whereas others have reported higher rates (14-45%)" . It seems to be false : 9% of malignant gliomas were nonenhancing or 21/58 (36.2%) of nonenhancing gliomas were malignant ; the same rate as the other.